Huadong Pharmaceutical (000963.SZ) subsidiary approved for clinical trial of HDM2006 tablets

Zhitong Finance App News, Huadong Pharmaceutical (000963.SZ) issued an announcement. Recently, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as “China-US Huadong”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” (Notice Numbers: 2024LP02360, 2024LP02361, 2024LP02362) approved and issued by the National Drug Administration (NMPA). The HDM2006 clinical trial application submitted by China and the US East China was approved. The drug is indicated for: advanced solid tumors.

HDM2006 tablets are novel, potent, highly selective, and orally absorbable proteolytic targeting chimeric (PROTAC) class 1 chemicals independently developed by Huadong in China and the US. East China and the US have global intellectual property rights. The approval of the HDM2006 clinical trial is an important milestone in the development process of this product, which will further enhance the company's core competitiveness in the field of tumor immunotherapy.